Organization
The US Oncology Network
18 abstracts
Abstract
Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).Org: University of Milan and European Institute of Oncology, IRCCS, Fudan University Shanghai Cancer Center, Division of Medical Oncology, National Cancer Centre of Singapore, National Cancer Center Hospital East, Kashiwa, Japan, Latin American Cooperative Oncology Group (LACOG),
Abstract
Impact of prior anticancer treatments on palbociclib (PAL) clinical outcomes in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC) in real-world settings.Org: Texas Oncology-Baylor Charles A. Sammons Cancer Center, The US Oncology Network, Mid-Illinois Hematology & Oncology Associates, Alabama Oncology, Novant Health Oncology Specialists,
Abstract
Elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (adv/mBC): Preliminary data from ELEVATE, a phase 1b/2, open-label, umbrella study.Org: Baylor University Medical Center, Texas Oncology, The US Oncology Network, International Breast Cancer Center (IBCC), Quironsalud Group,
Abstract
ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd).Org: The University of Texas MD Anderson Cancer Center, US Oncology Research/Maryland Oncology Hematology, Norton Healthcare, New York Presbyterian, Northwest Medical Specialties,
Abstract
Medicare reimbursement trends of biological reference agents and their biosimilars.Org: US Oncology Research, The Woodlands, Txinno Bioscience, McKesson, The US Oncology Network,
Abstract
Clinical trial participation and end-of-life care among older adults: A multi-center longitudinal observational cohort analysis of 121,717 patients with cancer.Org: Sarah Cannon Research Institute (SCRI), SCRI Oncology Partners, The US Oncology Network, Texas Oncology,
Abstract
Impact on biomarker documentation in community oncology by optimizing clinical decision support.Org: McKesson Specialty Health, The US Oncology Network, The Woodlands, TX,
Abstract
Clinical impact and financial feasibility of remote oncology pharmacists' roles in community oncology practices.Org: McKesson, The US Oncology Network, The Woodlands, TX,
Abstract
Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer.Org: Yale Cancer Center, Yale School of Medicine, Emory University School of Medicine, Nashville Breast Center, Dallas Surgical Group,
Abstract
5-year multicenter analysis of clinical trial participation and total cost of care for older adults with cancer.Org: Sarah Cannon Research Institute (SCRI), SCRI Oncology Partners, The US Oncology Network, Texas Oncology,
Abstract
Analyzing megestrol prescribing patterns in the Medicare cancer population in a community oncology network.Org: The US Oncology Network, The Woodlands, Txinno Bioscience, Dallas,
Abstract
Financial impact of fixed-dose versus weight-based dosing approaches for pembrolizumab and nivolumab in the Oncology Care Model for The US Oncology Network (The Network).Org: McKesson, The US Oncology Network, The Woodlands, TX,
Abstract
A paradox of size: Case-volume, financial outcomes, and risk in the enhancing oncology model baseline period.Org: The US Oncology Network, The Woodlands, TX, McKesson, Greenwood, IN,
Abstract
The impact of end-of-life quality metrics on date of death and hospice documentation over time.Org: The US Oncology Network, The Woodlands, TX, McKesson Specialty Health, Spring, TX, McKesson,
Abstract
Hospitalization risk in multiple myeloma episodes of care.Org: McKesson, The US Oncology Network, The Woodlands,
Abstract
Real-world cost of disease progression (PD) after frontline (1L) R-CHOP in diffuse large B-cell lymphoma (DLBCL): An analysis of a large US claims database.Org: Rocky Mountain Cancer Centers, The US Oncology Network, Aurora, CO, Genentech, South San Francisco, CA,
Abstract
Dose rounding bevacizumab and its biosimilars to reduce drug waste in the oncology care model in a community oncology network.Org: The U.S. Oncology Network, McKesson, The Woodlands, TX, Texas Oncology, The US Oncology Network,
Abstract
HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS.Org: Duke University Medical Center, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Grande Ospedale Metropolitano Niguarda and Università degli Studi di Milano,